PuSH - Publikationsserver des Helmholtz Zentrums München

Hofmann, K.* ; Fiedler, S.* ; Vierkotten, S. ; Weber, J.* ; Klee, S. ; Jia, J. ; Zwickenpflug, W.* ; Flockerzi, V.* ; Storch, U.* ; Yildirim, A.Ö. ; Gudermann, T.* ; Königshoff, M. ; Dietrich, A.*

Classical transient receptor potential 6 (TRPC6) channels support myofibroblast differentiation and development of experimental pulmonary fibrosis.

Biochim. Biophys. Acta 1863, 560-568 (2017)
Verlagsversion DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Pulmonary fibrosis (PF) is a chronic progressive lung disease without effective medical treatment options leading to respiratory failure and death within 3–5 years of diagnosis. The pathological process of PF is driven by aberrant wound-healing involving fibroblasts and myofibroblasts differentiated by secreted profibrotic transforming growth factor β (TGF-β1). Classical transient receptor potential 6 (TRPC6), a Na+- and Ca2 +-permeable cation channel, is able to promote myofibroblast conversion of primary rat cardiac and human dermal fibroblasts and TRPC6-deficiency impaired wound healing after injury. To study a potential role of TRPC6 in the development of PF we analyzed lung function, gene and protein expression in wild-type (WT) and TRPC6-deficient (TRPC6 −/−) lungs utilizing a bleomycin-induced PF-model. Fibrotic WT-mice showed a significant higher death rate while bleomycin-treated TRPC6-deficient mice were partly protected from fibrosis as a consequence of a lower production of collagen and an almost normal function of the respiratory system (reduced resistance and elastance compared to fibrotic WT-mice). On a molecular level TGF-β1 induced TRPC6 up-regulation, increased Ca2 + influx and nuclear NFAT localization in WT primary murine lung fibroblasts (PMLFs) resulting in higher stress fiber formation and accelerated contraction rates as compared to treated TRPC6-deficient fibroblasts. Therefore, we conclude that TRPC6 is an important determinant for TGF-β1-induced myofibroblast differentiation during fibrosis and specific channel inhibitors might be beneficial in a future treatment of PF.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
5.018
1.351
23
30
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Cell Contraction ; Myofibroblast Differentiation ; Primary Murine Lung Fibroblasts ; Pulmonary Fibrosis ; Tgf-β1 ; Trpc6; Cation Channel; Mesenchymal Transition; Extracellular-matrix; Lung Fibrosis; G-protein; In-vivo; Activation; Cells; Disease; Mice
Sprache englisch
Veröffentlichungsjahr 2017
Prepublished im Jahr 2016
HGF-Berichtsjahr 2016
ISSN (print) / ISBN 0006-3002
Quellenangaben Band: 1863, Heft: 2, Seiten: 560-568 Artikelnummer: , Supplement: ,
Verlag Elsevier
Verlagsort Amsterdam
POF Topic(s) 30503 - Chronic Diseases of the Lung and Allergies
30202 - Environmental Health
Forschungsfeld(er) Lung Research
PSP-Element(e) G-551800-001
G-505000-007
G-503100-001
Scopus ID 85003811129
PubMed ID 27932059
Erfassungsdatum 2016-12-22